Sempere A, Sanz G F, Senent L, de la Rubia J, Jarque I, López F, Arilla M J, Guinot M, Martín G, Martínez J
Department of Hematology, La Fe University Hospital, Valencia, Spain.
Bone Marrow Transplant. 1992 Dec;10(6):495-8.
Twenty-one adult patients with acute leukemia who underwent autologous blood stem cell transplantation (ABSCT) and who received acyclovir during the first 6 months after transplant to prevent varicella zoster virus (VZV) infection were studied retrospectively to determine the incidence and outcome of VZV infection after ABSCT. The cumulative risk of VZV infection was 32% by 1 year after transplant. No patient developed VZV while on prophylactic acyclovir but five (24%) had localized herpes zoster within 1 month of acyclovir withdrawal. There were no deaths related to VZV infection and only one patient had disseminated disease and post-herpetic neuralgia. These preliminary results suggest that the incidence and outcome of VZV infection after ABSCT largely parallel those reported in marrow transplant patients and that long-term acyclovir prophylaxis delays but does not prevent VZV infection. Prophylaxis of VZV infection after ABSCT requires new therapeutic approaches.
对21例接受自体血干细胞移植（ABSCT）且在移植后前6个月接受阿昔洛韦预防水痘带状疱疹病毒（VZV）感染的成年急性白血病患者进行回顾性研究，以确定ABSCT后VZV感染的发生率和结局。移植后1年时VZV感染的累积风险为32%。接受预防性阿昔洛韦治疗期间无患者发生VZV感染，但停用阿昔洛韦后1个月内有5例（24%）发生局部带状疱疹。无VZV感染相关死亡病例，仅1例患者发生播散性疾病和疱疹后神经痛。这些初步结果表明，ABSCT后VZV感染的发生率和结局与骨髓移植患者报道的情况基本相似，长期阿昔洛韦预防可延迟但不能预防VZV感染。ABSCT后VZV感染的预防需要新的治疗方法。
